<DOC>
	<DOCNO>NCT00502385</DOCNO>
	<brief_summary>The study conduct across multiple European centre assess safety tolerability multiple dos AZD2171 patient AML .</brief_summary>
	<brief_title>Phase I AZD2171 Patients With Relapsed Refractory AML Elderly Patients With DeNovo Secondary AML</brief_title>
	<detailed_description />
	<mesh_term>Cediranib</mesh_term>
	<criteria>Provision write informed consent Male/female , 18 yr WHO performance status 02 Disease respond relapse chemotherapy elderly patient suit chemotherapy Acute myeloid leukaemia arise previous chronic myeloid leukaemia acute myeloid leukaemia type FAB M3 Previous treatment new blood vessel formation ( antiangiogenic ) Chest Xray show leukaemia lung</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AML</keyword>
	<keyword>de novo secondary AML</keyword>
	<keyword>AZD2171</keyword>
</DOC>